Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
Noa Dagan et al.
Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Hagai Rossman et al.
Summary: This study analyzed data from the Israeli Ministry of Health to investigate the real-life impact of a national vaccination campaign on the dynamics of the COVID-19 pandemic. The findings revealed a significant and early decrease in COVID-19 cases and hospitalizations in individuals aged 60 years and older who were prioritized for vaccination, indicating the effectiveness of the vaccine rollout in reducing the spread of the virus.
Article
Biochemistry & Molecular Biology
Matan Levine-Tiefenbrun et al.
Summary: COVID-19 vaccines not only provide protection to individual vaccinees, but may also reduce viral load in breakthrough infections, potentially leading to lower infectiousness and further suppressing virus spread.
Review
Immunology
Hualei Xin et al.
Summary: The study found that the pooled median estimates of the mean, median, and 95th percentile for the incubation period of COVID-19 are 6.3 days, 5.4 days, and 13.1 days respectively. The estimates were significantly shorter before the epidemic peak in China compared to after, and variances were noticed for different methodological approaches.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Biochemistry & Molecular Biology
Oren Milman et al.
Summary: The study suggests that mass vaccination strategies not only protect vaccinated individuals, but also provide cross-protection to unvaccinated individuals, leading to a decrease in infection rates among the unvaccinated population, particularly in individuals under 16 years old.
Article
Medicine, General & Internal
Yinon M. Bar-On et al.
Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Public, Environmental & Occupational Health
Eli S. Rosenberg et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Medicine, General & Internal
Gabriel Chodick et al.
Summary: The short-term effectiveness of the first dose of the BNT162b2 vaccine against SARS-CoV-2 infection 13 to 24 days after immunization in a real-world setting was assessed, showing comparable results to the phase III randomized clinical trial.
Article
Multidisciplinary Sciences
Jesse Fajnzylber et al.
NATURE COMMUNICATIONS
(2020)
